Microbiotica and Genentech Partner to Study Microbiome Biomarkers and New IBD Therapies

Microbiotica and Genentech Partner to Study Microbiome Biomarkers and New IBD Therapies
Microbiotica, a company spun out of the Wellcome Sanger Institute, recently established a multiyear collaboration agreement with Genentech to discover, develop, and commercialize biomarkers, targets, and therapies for inflammatory bowel disease (IBD). The collaboration will focus on microbiome biomarker signatures and potential therapies based on Genentech’s IBD pipeline and on Microbiotica’s gut microbiome Reference Genome Database and Culture Collection, which enables gut bacterial identification at clinical-trial scale. Microbiotica will use its microbiome platform to analyze patient samples from clinical trials of Genentech’s investigational IBD medicines, with the goal of identifying microbiome biomarker signatures of drug response, new IBD targets, and live bacterial therapeutic products. Genentech, a member of the Roche Group, is the maker of etrolizumab (RG7413), an investigational therapy to treat both ulcerative colitis and Crohn’s disease. According to the terms of the agreement, Microbiotica could receive up to $534 million in upfront and milestone payments from Genentech. Genentech will retain the option to license assets that Microbiotica develops as a result of the research partnership. “This collaboration brings together a world-class pipeline of investigational IBD medic
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *